Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19606563 | 0.93 | CASP2 (0.61) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL21613628 | 0.91 | CASP2 (0.64) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL22340820 | 0.91 | CASP2 (0.64) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL11014644 | 0.91 | CASP2 (0.64) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL25950981 | 0.91 | CASP2 (0.64) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL12686586 | 0.86 | — | — | |
| SCHEMBL25091844 | 0.85 | CASP2 (0.68) | CASP2MEN1KMT2ACNR1NAAA | |
| SCHEMBL19401722 | 0.84 | MEN1 (0.46) | CASP2MEN1KMT2ACNR1NAAA | |
| SCHEMBL25140466 | 0.84 | MEN1 (0.52) | CASP2EPHX1MEN1KMT2ANAAA | |
| SCHEMBL25449079 | 0.83 | EPHX2 (0.65) | CNR1LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4227315-A1 | COMPOUND TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022140554-A1 | SMALL MOLECULE DEGRADERS OF PHOSPHATIDYLINOSITOL-5-PHOSPHATE 4-KINASE TYPE 2 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3922632-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2021-12-15 | — | — | EP | disclosed |
| WO-2008042480-A2 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20070224273-A1 | Multifunctional Supramolecular Hydrogels as Biomaterials | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (HK) | 2007-09-27 | — | — | US | disclosed |
| US-3969087-A | Gels of nonpolar liquids with N-acyl amino acids and derivatives thereof as gelling agents | AJINOMOTO CO., LTD. (JA) | 1976-07-13 | — | — | US | disclosed |